Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | NAAA | Q02083 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25203021 | 0.98 | SMN1; SMN2 (0.47) | SMN1; SMN2HTTALDH1A1LMNAKDM4E | |
| SCHEMBL30737050 | 0.94 | NAAA (0.46) | SMN1; SMN2HTTALDH1A1LMNAKDM4E | |
| SCHEMBL31465630 | 0.94 | NAAA (0.46) | SMN1; SMN2HTTALDH1A1LMNAKDM4E | |
| SCHEMBL18205376 | 0.93 | NAAA (0.48) | SMN1; SMN2HTTALDH1A1LMNAKDM4E | |
| SCHEMBL29084461 | 0.92 | L3MBTL1 (0.52) | SMN1; SMN2HTTALDH1A1LMNAKDM4E | |
| SCHEMBL1171919 | 0.91 | TSHR (0.52) | SMN1; SMN2ALDH1A1LMNAKDM4ETSHR | |
| SCHEMBL21768195 | 0.90 | ALDH1A1 (0.54) | SMN1; SMN2HTTALDH1A1LMNAKDM4E | |
| SCHEMBL22636310 | 0.85 | ALDH1A1 (0.54) | SMN1; SMN2HTTALDH1A1LMNAKDM4E | |
| SCHEMBL25030109 | 0.85 | ALDH1A1 (0.54) | SMN1; SMN2HTTALDH1A1LMNAKDM4E | |
| SCHEMBL5060301 | 0.84 | TDP1 (0.50) | ALDH1A1LMNAKDM4ENPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112996566-B | Chroman-4-one derivatives for the treatment and prevention of hepatitis B virus infection | 豪夫迈·罗氏有限公司 | 2023-11-03 | — | — | CN | disclosed |
| CN-116438177-A | Targeted chimeric compounds, pharmaceutical compositions containing same, and preparation methods and uses thereof | 江苏亚虹医药科技股份有限公司 | 2023-07-14 | — | — | CN | disclosed |
| US-11541050-B2 | Pyrimidine derivatives for the treatment of viral infections | JANSSEN SCIENCES IRELAND UC (IE) | 2023-01-03 | — | — | US | disclosed |
| US-20220388972-A1 | CHROMAN-4-ONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2022-12-08 | — | — | US | disclosed |
| US-20220388972-A1 | CHROMAN-4-ONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2022-12-08 | — | — | US | disclosed |
| US-20220388969-A1 | SUBSTITUTED 3,4-DIHYDROQUINAZOLINE FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2022-12-08 | — | — | US | disclosed |
| US-20220388969-A1 | SUBSTITUTED 3,4-DIHYDROQUINAZOLINE FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2022-12-08 | — | — | US | disclosed |
| EP-4038055-A1 | SUBSTITUTED 3,4-DIHYDROQUINAZOLINE FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | F. Hoffmann-La Roche AG (CH) | 2022-08-10 | — | — | EP | disclosed |
| WO-2022161166-A1 | TARGETING CHIMERIC COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, PREPARATION METHOD THEREFOR AND USE THEREOF | 江苏亚虹医药科技股份有限公司 | 2022-08-04 | — | — | WO | disclosed |
| CN-114502538-A | Substituted 3, 4-dihydroquinazolines for the treatment and prevention of hepatitis B virus infection | 豪夫迈·罗氏有限公司 | 2022-05-13 | — | — | CN | disclosed |
| US-10272085-B2 | Pyrimidine derivatives for the treatment of viral infections | JANSSEN SCIENCES IRELAND UC (IE) | 2019-04-30 | — | — | US | disclosed |
| US-20180207155-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UC (IE) | 2018-07-26 | — | — | US | disclosed |
| US-20180207155-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UC (IE) | 2018-07-26 | — | — | US | disclosed |
| EP-3330257-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | Janssen Sciences Ireland UC (IE) | 2018-06-06 | — | — | EP | disclosed |
| US-20170239245-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UC (IE) | 2017-08-24 | — | — | US | disclosed |
| US-20170239245-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UC (IE) | 2017-08-24 | — | — | US | disclosed |
| US-9422250-B2 | Pyrimidine derivatives for the treatment of viral infections | JANSSEN SCIENCES IRELAND UC (IE) | 2016-08-23 | — | — | US | disclosed |
| US-9422250-B2 | Pyrimidine derivatives for the treatment of viral infections | JANSSEN SCIENCES IRELAND UC (IE) | 2016-08-23 | — | — | US | disclosed |
| US-20140045849-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UC (IE) | 2014-02-13 | — | — | US | disclosed |
| US-20140045849-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UC (IE) | 2014-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220388972-A1 | CHROMAN-4-ONE DERIVATIVES FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HAVCR2, CYP4B1, CYP7A1 | SMN1; SMN2 3191/4885HTT 4455/4885ALDH1A1 920/4885 |
| US-20140045849-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | TYMP, UMPS, HPRT1 | SMN1; SMN2 3359/4885HTT 3104/4885ALDH1A1 1826/4885 |
| US-10272085-B2 | Pyrimidine derivatives for the treatment of viral infections | TYMP, UMPS, HPRT1 | SMN1; SMN2 3359/4885HTT 3104/4885ALDH1A1 1826/4885 |
| US-11541050-B2 | Pyrimidine derivatives for the treatment of viral infections | TYMP, UMPS, HPRT1 | SMN1; SMN2 3359/4885HTT 3104/4885ALDH1A1 1826/4885 |
| US-20220388969-A1 | SUBSTITUTED 3,4-DIHYDROQUINAZOLINE FOR THE TREATMENT AND PROPHYLAXIS OF HEPATITIS B VIRUS INFECTION | HAVCR2, CYP3A43, CYP2F1 | SMN1; SMN2 3902/4885HTT 4001/4885ALDH1A1 238/4885 |
| US-20180207155-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | TYMP, UMPS, HPRT1 | SMN1; SMN2 3359/4885HTT 3104/4885ALDH1A1 1826/4885 |
| US-20170239245-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | TYMP, UMPS, HPRT1 | SMN1; SMN2 3359/4885HTT 3104/4885ALDH1A1 1826/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.